LENSAR, Inc. $LNSR Stock Position Raised by Groupe la Francaise

Groupe la Francaise lifted its position in LENSAR, Inc. (NASDAQ:LNSR) by 99.5% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 251,400 shares of the company’s stock after buying an additional 125,400 shares during the quarter. Groupe la Francaise’s holdings in LENSAR were worth $3,311,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LNSR. Brandes Investment Partners LP lifted its stake in LENSAR by 3.5% in the second quarter. Brandes Investment Partners LP now owns 563,581 shares of the company’s stock valued at $7,422,000 after acquiring an additional 18,894 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of LENSAR during the 2nd quarter valued at $105,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of LENSAR in the 2nd quarter valued at $756,000. DCF Advisers LLC boosted its holdings in LENSAR by 1.3% in the second quarter. DCF Advisers LLC now owns 119,217 shares of the company’s stock worth $1,570,000 after purchasing an additional 1,500 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in LENSAR by 584.3% during the second quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company’s stock worth $62,000 after buying an additional 3,991 shares during the last quarter. Institutional investors and hedge funds own 40.15% of the company’s stock.

LENSAR Price Performance

LENSAR stock opened at $10.49 on Thursday. LENSAR, Inc. has a fifty-two week low of $7.13 and a fifty-two week high of $17.31. The firm has a fifty day moving average price of $11.35 and a two-hundred day moving average price of $12.32. The firm has a market cap of $125.30 million, a price-to-earnings ratio of -2.39 and a beta of 0.66.

LENSAR (NASDAQ:LNSR) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.23). LENSAR had a negative net margin of 87.12% and a negative return on equity of 737.30%. The business had revenue of $14.32 million during the quarter, compared to analyst estimates of $17.75 million.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENSAR in a research report on Wednesday, October 8th. Wall Street Zen raised LENSAR to a “hold” rating in a research note on Friday, November 28th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, LENSAR currently has a consensus rating of “Reduce” and a consensus target price of $15.00.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.